Qurient Past Earnings Performance
Past criteria checks 0/6
Qurient's earnings have been declining at an average annual rate of -0.9%, while the Biotechs industry saw earnings growing at 2.7% annually. Revenues have been growing at an average rate of 50.2% per year.
Key information
-0.9%
Earnings growth rate
9.8%
EPS growth rate
| Biotechs Industry Growth | 11.7% |
| Revenue growth rate | 50.2% |
| Return on equity | -42.9% |
| Net Margin | -251.2% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Qurient makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 8,752 | -21,984 | 7,485 | 17,271 |
| 30 Jun 24 | 8,753 | -21,289 | 7,007 | 17,025 |
| 31 Mar 24 | 8,995 | -19,838 | 6,899 | 15,720 |
| 31 Dec 23 | 9,032 | -21,117 | 7,358 | 16,765 |
| 30 Sep 23 | 8,652 | -22,805 | 6,556 | 19,290 |
| 30 Jun 23 | 8,560 | -26,492 | 8,091 | 21,666 |
| 31 Mar 23 | 8,609 | -27,601 | 8,746 | 22,167 |
| 31 Dec 22 | 8,469 | -25,457 | 8,812 | 19,687 |
| 30 Sep 22 | 9,963 | -24,157 | 10,494 | 17,248 |
| 30 Jun 22 | 9,171 | -21,021 | 9,881 | 14,063 |
| 31 Mar 22 | 6,895 | -21,135 | 8,783 | 14,488 |
| 31 Dec 21 | 4,886 | -22,848 | 8,003 | 16,438 |
| 30 Sep 21 | 1,378 | -24,600 | 7,719 | 17,609 |
| 30 Jun 21 | 0 | -24,400 | 7,063 | 17,858 |
| 31 Mar 21 | 0 | -22,439 | 6,949 | 15,727 |
| 31 Dec 20 | 0 | -20,498 | 6,760 | 13,707 |
| 30 Sep 20 | 0 | -21,020 | 5,985 | 14,724 |
| 30 Jun 20 | 0 | -20,638 | 5,765 | 14,499 |
| 31 Mar 20 | 0 | -21,332 | 5,472 | 15,658 |
Quality Earnings: A115180 is currently unprofitable.
Growing Profit Margin: A115180 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A115180 is unprofitable, and losses have increased over the past 5 years at a rate of 0.9% per year.
Accelerating Growth: Unable to compare A115180's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A115180 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (7.9%).
Return on Equity
High ROE: A115180 has a negative Return on Equity (-42.86%), as it is currently unprofitable.